Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 5/20 | 0.43 |
| ▸ | CD38 | P28907 | 6/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21174114 | 0.90 | ADORA1 (0.39) | ROCK2ADORA1 | |
| SCHEMBL21174216 | 0.86 | ADORA1 (0.41) | ADORA1 | |
| SCHEMBL21174050 | 0.86 | CTSD (0.40) | CD38ROCK2ADORA1S1PR1 | |
| SCHEMBL21174371 | 0.86 | PI4KB (0.43) | ADORA1 | |
| SCHEMBL21174144 | 0.85 | HCRTR1 (0.40) | ADORA1 | |
| SCHEMBL31456923 | 0.82 | ALDH1A1 (0.46) | ROCK2ADORA1 | |
| SCHEMBL27374784 | 0.82 | ALDH1A1 (0.46) | ROCK2ADORA1 | |
| SCHEMBL21174228 | 0.75 | PBK (0.40) | ADORA1 | |
| SCHEMBL30751453 | 0.74 | CCR1 (0.37) | ADORA1 | |
| SCHEMBL21174309 | 0.74 | PBK (0.38) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| EP-3514149-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3514149-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | PRSS8, PRSS1, PRSS2 | CYP4Z1 4524/4885NOS2 964/4885CD38 338/4885 |
| US-10774083-B2 | Heterocyclic amide compound | PRSS8, PRSS1, PRSS2 | CYP4Z1 4524/4885NOS2 964/4885CD38 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.